摘要
目的探讨初诊外周血中性粒细胞与淋巴细胞比值（NLR）对多发性骨髓瘤（MM）患者生存的影响。方法回顾性分析2007年1月至2015年12月南京医科大学附属无锡人民医院收治的195例MM患者临床资料，根据入院时的NLR分为低NLR组（NLR〈3）和高NLR组（NLR≥3），分析初诊时NLR与患者临床指标、治疗效果和总体生存期的关系。结果高NLR组61例，低NLR组134例。与低NLR组相比，高NLR组肌酐、血清钙偏高（均P〈0.05）。低NLR组初始诱导治疗后完全缓解率为32.1%（43/134），高于高NLR组的16.4%（10/61），两组差异有统计学意义（χ2=5.218，P=0.022）；低NLR组中位生存时间为38个月，长于高NLR组的27个月，两组差异有统计学意义（P=0.022）。单因素及多因素回归分析结果显示，NLR≥3是影响MM患者预后的危险因素之一（P=0.024），但不是独立危险因素（P=0.064）。结论MM患者的NLR与肌酐、血清钙相关，可以用来评估患者总体生存期以及诱导治疗缓解情况。
ObjectiveTo explore the effect of neutrophil-to-lymphocyte ratio （NLR） in peripheral blood on the survival of patients with multiple myeloma （MM）.MethodsThe clinical data of 195 patients with MM who were diagnosed in Wuxi People＇s Hospital Affiliated to Nanjing Medical University from January 2007 to December 2015 were retrospectively analyzed. According to NLR, the patients were divided into the low NLR group （NLR〈3） or high NLR group （NLR≥3）. The relationship between NLR and the parameters including clinical indicators, treatment response and overall survival of the patients was detected.ResultsThere were 61 cases in the high NLR group and 134 cases in the low NLR group. Compared with the low NLR group, creatinine and serum calcium in the high NLR group were higher （all P 〈 0.05）. Complete remission rate after initial induction therapy in the low NLR group （32.1%, 43/134） was higher than that in the high NLR group （16.4%, 10/61）, and there was a statistically significant difference （χ2=5.218, P=0.022）. Median survival time in the low NLR group （38 months） was longer than that in the high NLR group （27 months）, with a statistically significant difference （P=0.022）. Cox univariate and multivariate analysis showed NLR≥3 was a risk factor （P=0.024）, but not an independent risk factor （P=0.064）.ConclusionNLR is associated with creatinine and serum Ca, which can be used to evaluate the overall survival time and inductive treatment response in patients with MM.
作者
朱健伟
孙超
孙鸿丽
王欢
王婧
夏珺
郭宏锋
周新
Zhu Jianwei;Sun Chao;Sun Hongli;Wang Huan;Wang Jing;Xia Jun;Guo Hongfeng;Zhou Xin(Department of Hematology, Wuxi People＇s Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China)
出处
《白血病．淋巴瘤》
CAS
2018年第5期272-275,共4页
Journal of Leukemia & Lymphoma
